Remimazolam Tosilate + Propofol

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Anesthesia for Elective Surgery Patients

Conditions

Anesthesia for Elective Surgery Patients

Trial Timeline

May 13, 2019 → Dec 30, 2019

NCT ID

NCT03921775

About Remimazolam Tosilate + Propofol

Remimazolam Tosilate + Propofol is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Anesthesia for Elective Surgery Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT03921775. Target conditions include Anesthesia for Elective Surgery Patients.

What happened to similar drugs?

5 of 20 similar drugs in Anesthesia for Elective Surgery Patients were approved

Approved (5) Terminated (0) Active (15)

✅Fospropofol disodium, propofol + Fospropofol disodium, propofol + Fospropofol disodium, propofolEisaiApproved

✅Ciprofol + PropofolHaisco Pharmaceutical GroupApproved

✅CipepofolHaisco Pharmaceutical GroupApproved

✅Desflurane + PropofolBaxterApproved

✅Arm 1 Cataract Surgery performed with remimazolam as sedative + Arm 2 Cataract Surgery performed with standard of care sedativeEagle PharmaceuticalsApproved

🔄Ropivacaine + BupivacaineAstraZenecaPhase 3

🔄Sugammadex + neostigmineMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04400201	Phase 3	Completed	Jun 15, 2020	Oct 30, 2020	Sedation
NCT03921775	Phase 3	Completed	May 13, 2019	Dec 30, 2019	Anesthesia for Elective Surgery Patients
NCT03779061	Phase 3	Completed	Jun 28, 2018	Sep 28, 2018	Sedation
NCT03425474	Phase 3	Completed	Sep 1, 2017	Nov 10, 2017	Sedation
NCT03003884	Phase 2	Completed	Nov 1, 2016	Mar 1, 2017	Sedation
NCT02406872	Phase 2	Completed	Dec 1, 2014	Aug 1, 2015	General Anesthesia

Competing Products

20 competing products in Anesthesia for Elective Surgery Patients

See all competitors

Product	Company	Stage	Hype Score
Fospropofol disodium, propofol + Fospropofol disodium, propofol + Fospropofol disodium, propofol	Eisai	Approved	43
arm 1 + LUSEDRA + Propofol (arm 3)	Eisai	Phase 1	29
Remimazolam Tosilate for Injection	Jiangsu Hengrui Medicine	Pre-clinical	26
Remimazolam Tosylate	Jiangsu Hengrui Medicine	Phase 1	29
HR020602 injection + fentanyl injection ； remifentanil injection	Jiangsu Hengrui Medicine	Phase 2	35
Remimazolam Tosilate + Propofol	Jiangsu Hengrui Medicine	Phase 2	35
Remimazolam Tosilate + Propofol Injection.	Jiangsu Hengrui Medicine	Phase 2	35
Ropivacaine + Bupivacaine	AstraZeneca	Phase 3	40
Sugammadex	Merck	Phase 2	35
Sugammadex	Merck	Phase 2	35
Sugammadex + neostigmine	Merck	Phase 3	40
Sugammadex + Rocuronium + Sevoflurane + Propofol	Merck	Phase 3	40
Rocuronium + Sugammadex + Neostigmine + Atropine	Merck	Phase 3	40
Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance dose	Merck	Phase 3	40
Rocuronium bolus maintenance + rocuronium continuous infusion maintenance	Merck	Phase 3	40
Sugammadex + Rocuronium	Merck	Phase 3	40
Sugammadex + Neostigmine	Merck	Phase 3	40
sugammadex	Merck	Phase 3	40
Sugammadex + Succinylcholine + Rocuronium	Merck	Phase 3	40
Rocuronium bromide + Rocuronium bromide + Rocuronium bromide + Sevoflurane + Propofol	Merck	Phase 3	40